Literature DB >> 2347858

Adverse consequences of fluoxetine-MAOI combination therapy.

J P Feighner1, W F Boyer, D L Tyler, R J Neborsky.   

Abstract

The authors describe two series of patients: 12 treated simultaneously with fluoxetine and a monoamine oxidase inhibitor and 6 patients started on treatment with an MAOI 10 days or more after stopping fluoxetine treatment. All patients had extremely refractory depression and were treated in open fashion before general knowledge was obtained of the side effects that may accompany the fluoxetine-MAOI combination. During the fluoxetine-MAOI trial, most patients continued to receive other psychotropic combinations that had been partially helpful. The use of fluoxetine and an MAOI, either together or in close succession, was accompanied by a very high incidence of adverse effects, especially the "serotonergic syndrome." This syndrome was characterized by mental status changes, such as hypomania and confusion, and physical symptoms, such as myoclonus, hypertension, tremor, and diarrhea. Because of the high incidence of side effects and the lack of definite efficacy, the concurrent use of fluoxetine and MAOIs should generally be avoided. The long half-lives of fluoxetine and norfluoxetine, as well as the prolonged metabolic effects of MAOIs, may also dispose patients to an interaction if one of the drugs is started soon after stopping the other.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2347858

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  19 in total

1.  Serotonin syndrome in a renal transplant patient.

Authors:  E H Wong; N N Chan; K H Sze; K H Or
Journal:  J R Soc Med       Date:  2002-06       Impact factor: 5.344

Review 2.  Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies.

Authors:  R Amrein; T W Güntert; J Dingemanse; T Lorscheid; M Stabl; W Schmid-Burgk
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

4.  Antidepressant failure: augmentation or substitution?

Authors:  R T Joffe; A J Levitt
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

Review 5.  Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression.

Authors:  J C Fleishaker
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 6.  Drug therapy for geriatric depression.

Authors:  R Bressler; M D Katz
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 7.  Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness.

Authors:  M G Harris; P Benfield
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

Review 8.  Drug-induced myoclonus: frequency, mechanisms and management.

Authors:  Félix Javier Jiménez-Jiménez; Inmaculada Puertas; María de Toledo-Heras
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 10.  The serotonin syndrome. Implicated drugs, pathophysiology and management.

Authors:  K A Sporer
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.